ESR1 and invasive breast carcinoma: Another example is the selective estrogen receptor modulator raloxifene, which was approved by the FDA in 2007, to reduce the risk of invasive breast cancer in postmenopausal women at high risk [33], once again long before most systematic repurposing efforts were even started (see Figure 1).